A cost-effectiveness analysis of antimicrobial treatment of community-acquired pneumonia taking into account resistance in Belgium.

Martin, Monique; Moore, Lee; Quilici, Sibilia; Decramer, Marc; Simoens, Steven

Martin, Monique; Moore, Lee; Quilici, Sibilia; Decramer, Marc; Simoens, Steven.

Affiliation

Martin M; i3 Innovus, Uxbridge, UK. monique.martin@i3innovus.com

Curr Med Res Opin ; 24(3): 737-51, 2008 Mar.

Article in En | MEDLINE | ID: mdl-18230196

Subject(s)

Anti-Bacterial Agents/economics; Anti-Bacterial Agents/therapeutic use; Drug Costs; Drug Resistance, Multiple, Bacterial; Pneumonia, Bacterial/drug therapy; Pneumonia, Bacterial/economics; Amoxicillin/economics; Amoxicillin/therapeutic use; Aza Compounds/economics; Aza Compounds/therapeutic use; Belgium; Cefuroxime/economics; Cefuroxime/therapeutic use; Clarithromycin/economics; Clarithromycin/therapeutic use; Community-Acquired Infections/drug therapy; Community-Acquired Infections/economics; Cost-Benefit Analysis; Decision Support Techniques; Drug Therapy, Combination; Fluoroquinolones; Humans; Moxifloxacin; Pneumonia, Bacterial/microbiology; Quinolines/economics; Quinolines/therapeutic use

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Health context: 1_ASSA2030 Database: MEDLINE Main subject: Drug Costs / Pneumonia, Bacterial / Drug Resistance, Multiple, Bacterial / Anti-Bacterial Agents Type of study: Health_economic_evaluation / Prognostic_studies Limits: Humans Country/Region as subject: Europa Language: En Journal: Curr Med Res Opin Year: 2008 Document type: Article

Fulltext

XML

PubMed Links

Search on Google